Full Year 2025 Valneva SE Earnings Call Transcript

Mar 18, 2026 / 02:00 PM GMT

Release Date Price: $5.1

Transcript

Key Points

Positve

Valneva SE (INRLF) reported total revenues exceeding €170 million, slightly above 2024 levels, with nearly €160 million in product sales.
The company achieved a more than 20% reduction in operating cash burn through disciplined cash management.
Valneva SE (INRLF) advanced its Lyme disease vaccine program with partner Pfizer, with pivotal phase 3 results anticipated.
The company successfully refinanced its debt, enhancing financial flexibility.
Valneva SE (INRLF) is strategically positioned to become a leading vaccine biotech company, focusing on commercial growth and R&D optimization.

Negative

Total product sales decreased by 3.3% over 2024, primarily due to planned reductions in third-party sales and adverse currency impacts.
The company reported an operating loss of €82.1 million compared to an operating profit in 2024, driven by non-recurring income from the previous year.
Cost of goods and services increased by €8.6 million, impacted by an €8.5 million inventory write-off related to the chikungunya vaccine.
Research and development expenses increased to €85.3 million, driven by higher spending on phase 2 Shigella vaccine candidates and chikungunya vaccine post-marketing obligations.
Valneva SE (INRLF) anticipates further planned reductions in third-party product sales in 2026, potentially impacting overall revenue.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VLS.PA - Valneva SE
Full Year 2025 Valneva SE Earnings Call
Mar 18, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to Volliva's full year 2025 results and business update, conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, please press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.

Please note that today's conference is being recorded. I would now like to turn the conference over to your speaker, Tshu Adram, VP of Investor of Global Investor relations. Please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.